Rhythm Applies Oncology-Like Approach To Genetic Obesity

 
• By Alaric DeArment

CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.

genetic reasearch
Rhythm is developing Imcivree for rare, genetic diseases of obesity • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas